TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-10-15
Target enrollment:
Participant gender:
Summary
This is a phase 1b, open-Label clinical trial to determine the safety and tolerability and to
establish a preliminary recommended Phase 2 dose (RP2D) of TTAC-0001 administered in
combination with pembrolizumab in patients with recurrent glioblastoma.